R&D News | pharmaphorum

News

Lundbeck study knocks confidence in alpha-syn as CNS target

A phase 2 trial of Lundbeck’s alpha-synuclein-targeting drug Lu AF82422 has failed to reach statistical significance in patients with multiple system atrophy (MSA), althou

News

Novartis calls time on Tim3 drug sabatolimab in MDS

Novartis’ position as the frontrunner in the race to bring a Tim3-targeting drug to market has been lost after it pulled a phase 3 trial of its sabatolimab candidate.

News

Vertex scores double win with non-opioid pain drug

Vertex Pharma could be close to succeeding in the long-standing quest to find an alternative to potentially addictive opioids for the treatment of pain associated with com

News

US bill paints some Chinese biotechs as security threats

Legislation tabled in the US is seeking to block Chinese life sciences companies from claiming federal funding and contracts on the grounds they are a national security co

News

First human subject receives a Neuralink brain implant

Elon Musk’s Neuralink company has said it has implanted its wireless brain implant device into a human being for the first time, following FDA approval of clinical trials

News

Keytruda improves survival in early-stage kidney cancer

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell c

Lundbeck study knocks confidence in alpha-syn as CNS target

Novartis calls time on Tim3 drug sabatolimab in MDS

Vertex scores double win with non-opioid pain drug

US bill paints some Chinese biotechs as security threats

First human subject receives a Neuralink brain implant

Keytruda improves survival in early-stage kidney cancer

NHS study will pick apart mental illness with data science

How to meet your physicians where they are online

News

Editor's Picks